Literature DB >> 1826789

Mechanisms of vasopressin's anorectic effect.

W Langhans1, E Delprete, E Scharrer.   

Abstract

The present experiments investigated the effect of vasopressin (VP) on food intake in rats under various conditions. VP (1.25-10 micrograms/kg body weight = b.wt.) injected intraperitoneally (IP) at the onset of the dark phase of the lighting cycle inhibited feeding in a dose-dependent manner. The suppression of feeding induced by VP was primarily due to a delayed onset of the first meal after injection and was reversed by a V1-receptor antagonist (7 micrograms/kg b.wt., IP), by the Ca(++)-channel blocker verapamil (5 mg/kg b.wt., IP) and by the alpha-adrenergic receptor antagonist phentolamine (500 micrograms/kg b.wt.), but not by dissection of the hepatic branch of the vagus. In further experiments VP inhibited gastric emptying. This effect was not reversed by phentolamine. VP had also an aversive effect, but this effect was weaker than that of LiCl and probably not involved in VP-induced hypophagia. The results suggest that VP reduces feeding through a V1-receptor-mediated activation of an alpha-adrenergic mechanism. The inhibition of gastric emptying or a possible stimulation of hepatic oxidative metabolism by VP seems to be not essential for VP's effect on feeding. The results are consistent with a role of VP in stress-induced anorexia in rats.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826789     DOI: 10.1016/0031-9384(91)90251-i

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  12 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

Authors:  S V Koroleva; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2006-02

3.  Central angiotensin II has catabolic action at white and brown adipose tissue.

Authors:  Annette D de Kloet; Eric G Krause; Karen A Scott; Michelle T Foster; James P Herman; Randall R Sakai; Randy J Seeley; Stephen C Woods
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

4.  Oxytocin action in the ventral tegmental area affects sucrose intake.

Authors:  Kiersten Mullis; Kristen Kay; Diana L Williams
Journal:  Brain Res       Date:  2013-03-30       Impact factor: 3.252

5.  Autoantibodies against neuropeptides are associated with psychological traits in eating disorders.

Authors:  Sergueï O Fetissov; Jaanus Harro; Maiken Jaanisk; Anu Järv; Iris Podar; Jüri Allik; Ida Nilsson; Priya Sakthivel; Ann Kari Lefvert; Tomas Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-29       Impact factor: 11.205

Review 6.  Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans.

Authors:  James E Blevins; Denis G Baskin
Journal:  Physiol Behav       Date:  2015-05-23

Review 7.  Peptides and food intake.

Authors:  Carmen Sobrino Crespo; Aránzazu Perianes Cachero; Lilian Puebla Jiménez; Vicente Barrios; Eduardo Arilla Ferreiro
Journal:  Front Endocrinol (Lausanne)       Date:  2014-04-24       Impact factor: 5.555

8.  Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function.

Authors:  Luyi Zhou; Wei-Lun Sun; Amy B Young; Kunhee Lee; Jacqueline F McGinty; Ronald E See
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

9.  Arginine vasopressin: Direct and indirect action on metabolism.

Authors:  Mitsuhiro Yoshimura; Becky Conway-Campbell; Yoichi Ueta
Journal:  Peptides       Date:  2021-04-24       Impact factor: 3.750

10.  Involvement of prolactin-releasing peptide in the activation of oxytocin neurones in response to food intake.

Authors:  M Yamashita; Y Takayanagi; M Yoshida; K Nishimori; M Kusama; T Onaka
Journal:  J Neuroendocrinol       Date:  2013-05       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.